Investigators compared outcomes of chemotherapy conditioning with total body irradiation prior to hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia.
Incorporating 2 standardized documents into the process for supportive care measures improved outcomes for patients receiving HD-MTX.
Researchers report on results with CAR-T therapy in real-world populations of patients with ALL or NHL.
Young patients with newly diagnosed T-cell acute lymphoblastic leukemia showed favorable outcomes with nelarabine added to a treatment regimen.
As thromboembolism is a common side effect of ALL treatment, investigators assessed whether its occurrence in ALL and in the general adult population have a shared genetic basis.
The occurrence, severity, and need for treatment of cytokine release syndrome were key parameters in the assessment of CAR-T–related neurotoxicity risk.
Immunotherapy is changing the treatment paradigm for pediatric patients with relapsed acute lymphoblastic leukemia.
The implementation of risk-stratified therapy appears to have reduced late morbidity and mortality among survivors of pediatric acute lymphoblastic leukemia.
Risk-adapted therapy effectively prevents fungal infections and reduces neurotoxicity in children with leukemia.
A study compared the effects of intrathecal triple therapy to intrathecal methotrexate on disease-free survival among patients with B-ALL.
